Please assess the completion status of the following clinical trial:

Trial Title: Use of the Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female Europeans aged 18 years or older with moderate to severe hypertension (HTN)~Exclusion Criteria:~* Female patients of childbearing potential pregnant, lactating or planning to become pregnant during the trial period.~* Patients with serious disorders which may limit the ability to evaluate the efficacy or safety of the study medication, including cerebrovascular, cardiovascular, renal, respiratory, hepatic, gastrointestinal, endocrine or metabolic, haematological or oncological, neurological and psychiatric diseases.~* Patients having a history of the following within the last six months:~  * myocardial infarction,~ * unstable angina pectoris,~ * percutaneous coronary intervention,~ * severe heart failure,~ * hypertensive encephalopathy,~ * cerebrovascular accident (stroke) or~ * transient ischaemic attack.~* Patients with clinically significant abnormal laboratory values at screening.~* Patients with secondary HTN.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 4 (Type: EXPERIMENTAL): olmesartan medoxomil (OM) /hydrochlorothiazide (HCTZ) Tablet 40mg/0mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks
- 1 (Type: EXPERIMENTAL): olmesartan medoxomil (OM) /hydrochlorothiazide (HCTZ) tablets 40mg/25mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks
- 3 (Type: EXPERIMENTAL): olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 20mg/12.5mg + 40mg/0mg matching placebo tablet once daily for 8 weeks
- 2 (Type: EXPERIMENTAL): olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 40mg/12.5mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).